ADmit Therapeutics

ADmit Therapeutics is a Barcelona-based biotechnology company that has developed the MAP-AD® Test, the first CE-IVDR-certified IVD prognostic test for predicting progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. The test uses AI-powered epigenetic analysis — methylcytosine profiling via next-generation sequencing — combined with age, ApoE genotype, and clinical scores to deliver an early blood-based biomarker with no equivalent in clinical practice. The company serves pharmaceutical firms as an epigenetic patient-selection tool for Alzheimer's clinical trials, emerging from the Bellvitge Biomedical Research Institute and backed by the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator.